drugset / Trial / NCT00292370

Quetiapine Augmentation for Treatment-resistant PTSD

NCT00292370

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to compare the response of veterans with PTSD without an optimal response to paroxetine to quetiapine augmentation versus placebo.

Timeline

Start
2006-01
Primary completion
2008-12
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule 800 mg
Background Paroxetine Small molecule 60 mg